Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 101–200 of 2,517
Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 434
“However, 95% of tumorigenic p53 mutations are simply distributed in the central core domain where they abrogate the protein fold and its sequence-speci®c DNA binding a nity (Cho et al., 1994).”
BackgroundMethodInfluentialStructure–function–rescue: the diverse nature of common p53 cancer mutants
Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 434
“Close-up view of the N268D mutation site in the structure of T-p53C (PDB ID code 1UOL, molecule A; yellow) (Joerger et al., 2004) superimposed on the structure of the wild-type core domain (PDB ID code 1TSR, molecule A; gray) (Cho et al., 1994).”
BackgroundInfluentialSmall peptides activate the latent sequence-specific DNA binding function of p53
Hupp, T. R., Sparks, A., & Lane, D. P. (1995) · Cell · doi:10.1016/0092-8674(95)90165-5 · Cited by 434
“Inactivating point mutations usually map within the active site for sequencespecific DNA binding or within the central core DNA binding domain (Cho et al., 1994; Halazonetis and Kandil, 1993; Bargonetti et al., 1993).”
Oxidative damage to DNA: Formation, measurement, and biological significance
Cadet, J., Berger, M., Douki, T., & Ravanat, J. L. (1997) · Reviews of Physiology Biochemistry and Pharmacology, Volume 131 · doi:10.1007/3-540-61992-5_5 · Cited by 432
Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain
Wells, M., Tidow, H., Rutherford, T. J., Markwick, P., Jensen, M. R., Mylonas, E., Svergun, D. I., Blackledge, M., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801353105 · Cited by 434
“The first step is to solve the structures of individual core domains by using x-ray crystallography (6, 7) and NMR (8–10).”
BackgroundThioredoxin-dependent Redox Regulation of p53-mediated p21 Activation
Ueno, M., Masutani, H., Arai, R. J., Yamauchi, A., Hirota, K., Sakai, T., Inamoto, T., Yamaoka, Y., Yodoi, J., & Nikaido, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35809 · Cited by 428
Protein-DNA interactions: a structural analysis
Jones, S., van Heyningen, P., Berman, H. M., & Thornton, J. M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2659 · Cited by 424
Russo, A., Bazan, V., Iacopetta, B., Kerr, D., Soussi, T., & Gebbia, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.471 · Cited by 416
“These included the L2 loop (codons 163 to 195), L3 loop (codons 236 to 251), LSH motif (codons 271 to 286) as well as the highly conserved areas II (codons 117 to 142), III (codons 171 to 181), IV (codons 234 to 258), and V (codons 270 to 286).(34) Mutations in the hotspot codons were also examined (codons 175, 196, 2…”
BackgroundProtein‐misfolding diseases and chaperone‐based therapeutic approaches
Chaudhuri, T. K., & Paul, S. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05181.x · Cited by 419
The transcriptional targets of p53 in apoptosis control
Yu, J., & Zhang, L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.189 · Cited by 420
p53-Dependent apoptosis pathways
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)82002-9 · Cited by 418
Steels, E., Paesmans, M., Berghmans, T., Branle, F., Lemaitre, F., Mascaux, C., Meert, A. P., Vallot, F., Lafitte, J. J., & Sculier, J. P. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00062201 · Cited by 418
“However, not all mutated proteins lose their physiological function and in the case of p53, the disturbance of the regulation of the cell cycle depends on the site of the mutation [101, 102 ].”
BackgroundDrosophila p53 Is a Structural and Functional Homolog of the Tumor Suppressor p53
Ollmann, M., Young, L. M., Di Como, C. J., Karim, F., Belvin, M., Robertson, S., Whittaker, K., Demsky, M., Fisher, W. W., Buchman, A., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)80626-1 · Cited by 412
“…critical for MDM2 binding are not conserved in Dmp53.residues identified in human p53 as critical for DNA sequence recognition and coordination of a zinc ion p53-related sequences have been described previously in invertebrates, including clams (Barker et al.,(Figures 1B and 1C) (Cho et al., 1994).”
BackgroundMethodInfluentialp73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Di Como, C. J., Gaiddon, C., & Prives, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
“However, why were we not able to detect wild-type p73 complexed with wild-type p53 by coimmunoprecipitation? The crystal structure of the DNA binding domain of p53 bound to its cognate site (9) has helped to explain how mutations in this region interfere with DNA binding.”
BackgroundTumors associated with p53 germline mutations: a synopsis of 91 families.
Kleihues, P., Schäuble, B., Hausen, A. Z., Estève, J., & Ohgaki, H. (1997) · Europe PMC (PubMed Central) · Cited by 488
Stone, E. A., & Sidow, A. (2005) · Genome Research · doi:10.1101/gr.3804205 · Cited by 410
“This median was used to color C .( C) Median MAPP scores plotted on the crystal structure of human p53 ( Cho et al. 1994; DeLano 2002).”
MethodTP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Leroy, B., Anderson, M., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22552 · Cited by 408
Thermodynamic stability of wild-type and mutant p53 core domain
Bullock, A. N., Henckel, J., DeDecker, B. S., Johnson, C. M., Nikolova, P. V., Proctor, M. R., Lane, D. P., & Fersht, A. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14338 · Cited by 405
Structural Basis of DNA Recognition by p53 Tetramers
Kitayner, M., Rozenberg, H., Kessler, N., Rabinovich, D., Shaulov, L., Haran, T. E., & Shakked, Z. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.015 · Cited by 408
Structure of IRF-1 with bound DNA reveals determinants of interferon regulation
Escalante, C. R., Yie, J., Thanos, D., & Aggarwal, A. K. (1998) · Nature · doi:10.1038/34224 · Cited by 397
COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system
Bech-Otschir, D. (2001) · The EMBO Journal · doi:10.1093/emboj/20.7.1630 · Cited by 397
Ho, E., & Ames, B. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222679399 · Cited by 392
Iron, hemochromatosis, and hepatocellular carcinoma
Kowdley, K. V. (2004) · Gastroenterology · doi:10.1016/j.gastro.2004.09.019 · Cited by 391
Structure and function of the multifunctional DNA-repair enzyme exonuclease III
Mol, C. D., Kuo, C.-F., Thayer, M. M., Cunningham, R. P., & Tainer, J. A. (1995) · Nature · doi:10.1038/374381a0 · Cited by 389
Gauch Jr, H. G. (2002) · doi:10.1017/cbo9780511815034 · Cited by 385
Collins, K., Jacks, T., & Pavletich, N. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.2776 · Cited by 380
Self-citationThe C. elegans homolog of the p53 tumor suppressor is required for DNA damage-induced apoptosis
Schumacher, B., Hofmann, K., Boulton, S., & Gartner, A. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00534-6 · Cited by 360
“In both cases, 1b) [12].”
Li-Fraumeni syndrome – a molecular and clinical review
Varley, J., Evans, D., & Birch, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.328 · Cited by 358
The Tumor Suppressor p53: From Structures to Drug Discovery
Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 357
Recognition of Specific DNA Sequences
Garvie, C. W., & Wolberger, C. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00392-6 · Cited by 357
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs
Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 353
Structure of serum response factor core bound to DNA
Pellegrini, L., Tan, S., & Richmond, T. J. (1995) · Nature · doi:10.1038/376490a0 · Cited by 353
Genetic aberrations and survival in plasma cell leukemia
Tiedemann, R. E., Gonzalez-Paz, N., Kyle, R. A., Santana-Davila, R., Price-Troska, T., Van Wier, S. A., Chng, W. J., Ketterling, R. P., Gertz, M. A., Henderson, K., et al. (2008) · Leukemia · doi:10.1038/leu.2008.4 · Cited by 349
Selivanova, G., Iotsova, V., Okan, I., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 343
Jayaraman, L., & Prives, C. (1995) · Cell · doi:10.1016/s0092-8674(05)80007-8 · Cited by 345
“The experiments described above suggested that the p53 C-terminus, through its interactions with short single strands, may be capable of increasing the~affinity of the i ?, ~ .... 4 2 3 4 i~ i i~i iii i 1 2 3 4 Figure 2. central sequence-specific DNA-binding domain with a cognate site.”
BackgroundInfluentialmiR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer
Gallardo, E., Navarro, A., Viñolas, N., Marrades, R. M., Diaz, T., Gel, B., Quera, A., Bandres, E., Garcia-Foncillas, J., Ramirez, J., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp219 · Cited by 342
“About 55% of NSCLCs are reported to contain mutations of the p53 gene, most of which are point mutations located in the region between exons 5 and 8[14;15], which contains the DNA binding site of the p53 protein[16].”
BackgroundMathe, E. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj518 · Cited by 340
“The GV values were mapped on to the 3D structure of the DBD of p53 (26), comprising residues 96 to 289 (Figure 3).”
MethodProtein Folding and Mechanisms of Proteostasis
Díaz-Villanueva, J., Díaz-Molina, R., & García-González, V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817193 · Cited by 338
“Loops and the loop-sheet-helix motif represent the conserved regions of the core domain, and contain the majority of the p53 mutations identified in tumors [235].”
BackgroundThe role of p53 in chemosensitivity and radiosensitivity
El-Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206949 · Cited by 337
“The crystal structure of p53 with its DNAbinding site revealed that hotspots for mutational inactivation in cancer represent contact points between p53 and DNA (Cho et al., 1994). p53 is conserved in Drosophila and binds to DNA, and activates genes involved in programmed cell death (Ollmann et al., 2000).”
BackgroundInfluentialA-form Conformational Motifs in Ligand-bound DNA Structures
Lu, X.-J., Shakked, Z., & Olson, W. K. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3690 · Cited by 331
“the A-philic d(AGG) d(TCC) sequences in the diphtheria tox repressor (NDB entry: pd0004) (White et al., 1998), the deformable AC GT steps in the DNA bound to both HhaI methyltransferase (NDB entry: pd0019) (O’Gara et al., 1998) and the helix-loop-helix leucine zipper transcription factor Max (NDB entry: pdt042) (Brown…”
BackgroundLocal Structural Elements in the Mostly Unstructured Transcriptional Activation Domain of Human p53
Lee, H., Mok, K. H., Muhandiram, R., Park, K.-H., Suk, J.-E., Kim, D.-H., Chang, J., Sung, Y. C., Choi, K. Y., & Han, K.-H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003107200 · Cited by 329
Willis, A., Jung, E. J., Wakefield, T., & Chen, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207396 · Cited by 330
“The contact site mutants, for example, R248W and R273H, have an altered residue at a site that, in the wild-type protein, directly contacts DNA (Cho et al., 1994; Rolley et al., 1995).”
BackgroundTumor-Suppressor Functions of the TP53 Pathway
Aubrey, B. J., Strasser, A., & Kelly, G. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026062 · Cited by 327
“1993) that binds to specific Tp53 response elements in genomic DNA (el-Deiry et al. 1992; Cho et al. 1994) to direct the transcription of a large number of protein-coding genes (Riley et al.”
BackgroundGeisler, S. B., Lønning, P. E., Aas, T., Johnsen, H., Fluge, Ø., Haugen, D. F., Lillehaug, J. R., Akslen, L. A., & Børresen‐Dale, A. (2001) · PubMed · Cited by 326
Zhang, W., Geiman, D. E., Shields, J. M., Dang, D. T., Mahatan, C. S., Kaestner, K. H., Biggs, J. R., Kraft, A. S., & Yang, V. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000062200 · Cited by 327
p63 and p73, the ancestors of p53
Dotsch, V., Bernassola, F., Coutandin, D., Candi, E., & Melino, G. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004887 · Cited by 326
“The crystal structure of human p53 bound to a consensus p53 DNA sequence has revealed that these sequence domains contain the residues that are important for DNA binding as well as for coordinating a structurally important zinc ion (Cho et al. 1994; Huyen et al. 2004).”
BackgroundCrystallographic structure of the T domain–DNA complex of the Brachyury transcription factor
Müller, C. W., & Herrmann, B. G. (1997) · Nature · doi:10.1038/39929 · Cited by 324
Tahirov, T. H., Inoue-Bungo, T., Morii, H., Fujikawa, A., Sasaki, M., Kimura, K., Shiina, M., Sato, K., Kumasaka, T., Yamamoto, M., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00271-9 · Cited by 327
“Within the p53-DNA complex (Cho et al., 1994), the minor tated molecules in acute leukemia and related diseases (Cleary, 1999; Speck et al., 1999; Lutterbach and Hiebert,groove–interacting loop (L3), which sandwiches the DNA sugar-phosphate ridge with the major groove–inter- 2000), whereas…”
BackgroundInfluentialHigh mobility group protein-1 (HMG-1) is a unique activator of p53
Jayaraman, L., Moorthy, N. C., Murthy, K. G. K., Manley, J. L., Bustin, M., & Prives, C. (1998) · Genes & Development · doi:10.1101/gad.12.4.462 · Cited by 321
“The region in p53 that contributes to sequence-specific DNA binding spans the central portion of the protein, extending approximately from amino acid 100 to 300 (Cho et al. 1994 and references therein).”
BackgroundAllele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
“Structural studies of the p53 DNA binding domain indicate that the zinc ion is coordinated by four amino acids (C176, H179, C238, and C242; Cho et al., 1994; Joerger et al., 2005; Wong et al., 1999 ).”
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway.
Wang, X. W., Vermeulen, W., Coursen, J. D., Gibson, M., Lupold, S. E., Forrester, K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J. H., et al. (1996) · Genes & Development · doi:10.1101/gad.10.10.1219 · Cited by 313
PML Is a Direct p53 Target that Modulates p53 Effector Functions
de Stanchina, E., Querido, E., Narita, M., Davuluri, R. V., Pandolfi, P. P., Ferbeyre, G., & Lowe, S. W. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00062-0 · Cited by 312
(2000) · doi:10.1038/76797 · Cited by 264
Rossi, D., Cerri, M., Deambrogi, C., Sozzi, E., Cresta, S., Rasi, S., De Paoli, L., Spina, V., Gattei, V., Capello, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1630 · Cited by 310
Van Meir, E. G., Polverini, P. J., Chazin, V. R., Su Huang, H.-J., de Tribolet, N., & Cavenee, W. K. (1994) · Nature Genetics · doi:10.1038/ng1094-171 · Cited by 307
Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy
Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308
Zinc Coordination Environments in Proteins as Redox Sensors and Signal Transducers
Maret, W. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1419 · Cited by 307
Role of Cysteine Residues in Regulation of p53 Function
Rainwater, R., Parks, D., Anderson, M. E., Tegtmeyer, P., & Mann, K. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3892 · Cited by 306
“Crystallography studies with the central DNA-binding domain of human p53 (6) show that each monomer of human p53 does in fact coordinate one zinc ion through amino acids Cys-176, His-179, Cys-238, and Cys-242.”
BackgroundResultInfluentialSoussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305
Allosteric activation of latent p53 tetramers
Hupp, T. R., & Lane, D. P. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00195-0 · Cited by 301
Kaeser, M. D., & Iggo, R. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012283399 · Cited by 302
Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.
Rowan, S., Ludwig, R. L., Haupt, Y., Bates, S., Lu, X., Oren, M., & Vousden, K. H. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00418.x · Cited by 301
Human TAFII31 protein is a transcriptional coactivator of the p53 protein.
Lu, H., & Levine, A. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.5154 · Cited by 301
Structure of the replicative helicase of the oncoprotein SV40 large tumour antigen
Li, D., Zhao, R., Lilyestrom, W., Gai, D., Zhang, R., DeCaprio, J. A., Fanning, E., Jochimiak, A., Szakonyi, G., & Chen, X. S. (2003) · Nature · doi:10.1038/nature01691 · Cited by 300
“On the p53 side, mapping the residues important for binding LTag to the known p53 structur”
BackgroundHainaut, P., Soussi, T., Shomer, B., Hollstein, M., Greenblatt, M., Hovig, E., Harris, C. C., & Montesano, R. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.1.151 · Cited by 298
Ren, Z.-P., Pontén, F., Nistér, M., & Pontén, I. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960621)69:3<174::aid-ijc4>3.0.co;2-x · Cited by 96
Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review
Montesano, R., Holestein, M., & Hainaui, P. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960621)69:3<225::aid-ijc13>3.0.co;2-6 · Cited by 297
The p53MH algorithm and its application in detecting p53-responsive genes
Hoh, J., Jin, S., Parrado, T., Edington, J., Levine, A. J., & Ott, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132268899 · Cited by 295
Valente, L. J., Gray, D. H. D., Michalak, E. M., Pinon-Hofbauer, J., Egle, A., Scott, C. L., Janic, A., & Strasser, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.012 · Cited by 291
“The p53 protein mostly resides in the nucleus where, upon activation, it can bind as a homotetramer to specific DNA sequences and thereby regulate the transcription of select target genes (Cho et al., 1994).”
BackgroundTP53 mutations in human skin cancers
Giglia-Mari, G., & Sarasin, A. (2003) · Human Mutation · doi:10.1002/humu.10179 · Cited by 292
“…and Pfeifer, 1995], and to undertake a rapid deamination into thymine [Tu et al., 1998]; 3) the Arg 248 is an amino acid in direct contact with the DNA [Cho et al., 1994], hence when mutated it disrupts the DNA binding functions of the P53 protein and therefore its transactivation properties.”
BackgroundSplit-Hand/Split-Foot Malformation Is Caused by Mutations in the p63 Gene on 3q27
Ianakiev, P., Kilpatrick, M. W., Toudjarska, I., Basel, D., Beighton, P., & Tsipouras, P. (2000) · The American Journal of Human Genetics · doi:10.1086/302972 · Cited by 292
“Amino acid residues 123–340 of the p63 gene (GenBank accession number BAA32593), which correspond to the DNA-binding domain of the TP53 protein (Cho et al. 1994), were folded using a modeling program (Lund et al. 1997).”
BackgroundMethodInfluentialCrystal Structure of lac Repressor Core Tetramer and Its Implications for DNA Looping
Friedman, A. M., Fischmann, T. O., & Steitz, T. A. (1995) · Science · doi:10.1126/science.7792597 · Cited by 291
Venot, C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4668 · Cited by 292
“, 1995) and the central specific DNA-binding domain (amino acids 102–292) (Bargonetti et al., 1993; Pavletich et al., 1993; Cho et al., 1994).”
BackgroundInfluentialThe rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Del Sal, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 289
“Derived from Protein Data Bank (PDB) ID: 1TUP (33).”
BackgroundMethodTumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage
Cox, L. S., & Lane, D. P. (1995) · BioEssays · doi:10.1002/bies.950170606 · Cited by 287
Repression of RNA Polymerase I Transcription by the Tumor Suppressor p53
Zhai, W., & Comai, L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.5930-5938.2000 · Cited by 289
“Plasmids for the expression of glutathione Stransferase (GST) fusion human p53 fragments, pGThp53N ( 1-160 ), pGThp53C1 (160-318), pGThp53C2 (318-393), and pGThp53C (160-393), have been described previously (24).”
BackgroundRedox homeostasis: the linchpin in stem cell self-renewal and differentiation
Wang, K., Zhang, T., Dong, Q., Nice, E. C., Huang, C., & Wei, Y. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.50 · Cited by 288
Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases
Uversky, V. N., Davé, V., Iakoucheva, L. M., Malaney, P., Metallo, S. J., Pathak, R. R., & Joerger, A. C. (2014) · Chemical Reviews · doi:10.1021/cr400713r · Cited by 288
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
Hanel, W., Marchenko, N., Xu, S., Xiaofeng Yu, S., Weng, W., & Moll, U. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.17 · Cited by 283
“Both mutations are located within the L3 loop of p53.(11) The R248 residue is in direct physical contact with the minor groove of DNA and has been traditionally called a ‘contact’ mutation.”
Reles, A., Wen, W., Schmider, A., Gee, C., Runnebaum, I. B., Kilian, U., Jones, L. A., El‐Naggar, A. K., Minguillon, C., Schönborn, I., et al. (2001) · PubMed · Cited by 282
The p53 network: cellular and systemic DNA damage responses in cancer and aging
Vaddavalli, P. L., & Schumacher, B. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.010 · Cited by 279
Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A
Bochkareva, E., Kaustov, L., Ayed, A., Yi, G.-S., Lu, Y., Pineda-Lucena, A., Liao, J. C. C., Okorokov, A. L., Milner, J., Arrowsmith, C. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504614102 · Cited by 275
p53 mutation heterogeneity in cancer
Soussi, T., & Lozano, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.190 · Cited by 275
Latent and active p53 are identical in conformation.
Ayed, A., Mulder, F. A. A., Yi, G., Lu, Y., Kay, L. E., & Arrowsmith, C. H. (2001) · Nature Structural Biology · doi:10.1038/nsb0901-756 · Cited by 336
p53 Contains Large Unstructured Regions in its Native State
Bell, S., Klein, C., Müller, L., Hansen, S., & Buchner, J. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00848-3 · Cited by 275
Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP
Zheng, N., Fraenkel, E., Pabo, C. O., & Pavletich, N. P. (1999) · Genes & Development · doi:10.1101/gad.13.6.666 · Cited by 271
“Similar arginine-minor groove contacts, associated with an A/T rich sequence and with a compressed minor groove have been observed in other protein–DNA complexes (Aggarwal et al. 1988; Clark et al. 1993; Cho et al. 1994).”
BackgroundSelf-citationLe Calvez, F., Mukeria, A., Hunt, J. D., Kelm, O., Hung, R. J., Tanière, P., Brennan, P., Boffetta, P., Zaridze, D. G., & Hainaut, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0551 · Cited by 273
The role of tetramerization in p53 function
Chène, P. (2001) · Oncogene · doi:10.1038/sj.onc.1204373 · Cited by 271
“It has been shown, for example, that several interactions at the interface with the DBD may stabilize the tetramers (Cho et al., 1994).”
BackgroundHuman Gene Mutation Database?A biomedical information and research resource
Krawczak, M., Ball, E. V., Fenton, I., Stenson, P. D., Abeysinghe, S., Thomas, N., & Cooper, D. N. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<45::aid-humu10>3.0.co;2-t · Cited by 273
Hepatocellular Carcinoma: From Gene to Public Health
Montesano, R., Hainaut, P., & Wild, C. P. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.24.1844 · Cited by 269
Soussi, T., Dehouche, K., & B�roud, C. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<105::aid-humu19>3.0.co;2-g · Cited by 271
Mutant p53: an oncogenic transcription factor
Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., & Blandino, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210296 · Cited by 269
“Structural studies have allowed to classify p53 mutant proteins in two large categories (Cho et al., 1994; Bullock and Fersht, 2001; Joerger et al., 2005): (a) DNA contactdefective mutants (His273, Trp248), which include those mutants whose mutation impacts on the residues composing the DNA/protein…”
BackgroundHartwig, A. (2001) · Antioxidants & Redox Signaling · doi:10.1089/15230860152542970 · Cited by 269
“Cys 3 His 1 zinc coordination is also present in the metal-binding domain of the tumor suppressor protein p53; upon activation in response to stress, the zinc finger mediates high affinity for specific DNA sequences (14).”
Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M. V., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rüdiger, S., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241629998 · Cited by 268
Luscombe, N. M., & Thornton, J. M. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00571-5 · Cited by 265
Solution structure of the tetrameric minimum transforming domain of p53
Lee, W., Harvey, T. S., Yin, Y., Yau, P., Litchfield, D., & Arrowsmith, C. H. (1994) · Nature Structural & Molecular Biology · doi:10.1038/nsb1294-877 · Cited by 265
Kadia, T. M., Jain, P., Ravandi, F., Garcia‐Manero, G., Andreef, M., Takahashi, K., Borthakur, G., Jabbour, E., Konopleva, M., Daver, N. G., et al. (2016) · Cancer · doi:10.1002/cncr.30203 · Cited by 261
“46 Platelets, 10(3)/lL 32 (4-153) 39 (1-708) .”
The Chaperone-associated Ubiquitin Ligase CHIP Is Able to Target p53 for Proteasomal Degradation
Esser, C., Scheffner, M., & Höhfeld, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501574200 · Cited by 261
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261
How p53 binds DNA as a tetramer
McLure, K. G., & Lee, P. W. K. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3342 · Cited by 260
“…as the primary intra-dimer, inter-monomer interaction in the model of tetramers binding DNA as one dimer binding to quarter-sites one and three, the other dimer binding to sites two and four (Cho et al., 1994; Lee et al., 1994; Jeffrey et al., 1995; Arrowsmith and Morin, 1996; Pennisi, 1996).”
BackgroundMethodInfluential
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.